ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 107,900 shares, an increase of 9.3% from the May 31st total of 98,700 shares. Based on an average trading volume of 52,600 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.2% of the shares of the stock are short sold.

ABIVAX Société Anonyme Trading Up 2.6 %

ABIVAX Société Anonyme stock opened at $13.56 on Tuesday. The stock has a 50-day moving average price of $14.07 and a 200 day moving average price of $13.36. ABIVAX Société Anonyme has a 52 week low of $7.99 and a 52 week high of $17.02. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.23.

Institutional Trading of ABIVAX Société Anonyme

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $13,630,000. Capstone Investment Advisors LLC purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $618,000. Ghisallo Capital Management LLC purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $642,000. Commodore Capital LP purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $20,277,000. Finally, Blackstone Inc. purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $25,345,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Analysts Set New Price Targets

ABVX has been the subject of a number of research analyst reports. Morgan Stanley raised their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the company an “equal weight” rating in a research report on Thursday, April 11th. BTIG Research initiated coverage on ABIVAX Société Anonyme in a research report on Monday, May 20th. They issued a “buy” rating and a $43.00 price target for the company. Piper Sandler initiated coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued an “overweight” rating and a $42.00 price target for the company. Finally, Guggenheim initiated coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued a “buy” rating and a $50.00 price target for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.20.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.